REFERENCES
- Heufelder A E, Bahn R S. Graves’ immunoglobulins and cytokines stimulate the expression of intercellular adhesion molecule-1 (ICAM-1) in cultured Graves’ orbital fibroblasts. Eur J Clin Invest 1992; 22: 529–537
- Burch H B, Wartofsky L. Graves’ ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1993; 14: 747–793
- Sorisky A, Pardasani D, Gagnon A, Smith T J. Evidence of adipocyte differentiation in human orbital fibroblast in primary culture. J Clin Endocrinol Metab 1996; 81: 3428–3431
- Heufelder AE. Retro-orbital autoimmunity. Bailliere's Clin Endocrinol Metab 1997; 11: 499–520
- Raff MC. Social controls on cell survival and cell death. Nature 1992; 356: 397–400
- Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456–1462
- Nagata S. Apoptosis by death factor. Cell 1997; 88: 355–365
- Green DR. Apoptotic pathways: the roads to ruin. Cell 1998; 94: 695–698
- Eguchi K. Apoptosis in autoimmune diseases. Intern Med 2001; 40: 275–284
- Prummel M F, Bakker A, Wiersinga W M, Baldeschi L, Mourits M P, Kendall-Taylor P, Perros P, Neoh C, Dickinson A J, Lazarus J H, Lane C M, Heufelder A E, Kahaly G J, Pitz S, Orgiazzi J, Hullo A, Pinchera A, Marcocci C, Sartini M S, Rocchi R, Nardi M, Krassas G E, Halkias A. Multi-center study on the characteristics and treatment strategies of patients with Graves’ orbitopathy: the first Europian Group on Graves Orbitopathy experience. Eur J Endocrinol 2003; 148: 491–495
- Mourits M P, Prummel M F, Wiersinga W M, Koornneef L. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol 1997; 47: 9–14
- Donaldson S S, Bagshaw M A, Kriss J P. Supervoltage orbital radiotherapy for Graves’ ophthalmopathy. J Clin Endocrinol Metab 1973; 37: 276–285
- Nunery W R, Martin R T, Heinz G W, et al. The association of cigarette smoking with clinical subtypes of ophthalmic Graves’ disease. Ophthal Plast Reconstr Surg 1993; 9: 7714
- Heufelder AE. Pathogenesis of ophthalmopathy in autoimmune thyroid disease. Rev Endocr Metab Disord 2000; 1: 87–95
- Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449–1456
- Giordano C, Stassi G, De Maria R, Todaro M, Richiusa P, Papoff G, Ruberti G, Bagnasco M, Testi R, Galluzzo A. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 1997; 275: 960–963
- Koga M, Hiromatsu Y, Jimi A, Inoue Y, Nonaka K. Possible involvement of Fas mediated apoptosis in eye muscle tissue from patients with thyroid-associated ophthalmopathy. Thyroid 1998; 8: 311–318
- Kumar S, Bahn RS. Relative overexpression of macrophage-derived cytokines in orbital adipose tissue from patients with Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2003; 88: 4246–4250
- Gerding M N, Prummel M F, Wiersinga W M. Assessment of disease activity in Graves’ ophthalmopathy by orbital ultrasonography and clinical parameters. Clin Endocrinol 2000; 52: 641–646
- Bartelena L, Martino E, Marcocci C, Bogazzi F, Panicucci M, Velluzzi F, Loviselli A, Pinchera A. More on smoking habits and Graves’ ophthalmopathy. J Endocrinol Invest 1989; 12: 733–737
- Bartelena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev 2000; 21: 168–199